HK Innoen Receives Approval for Two Comprehensive Nutritional Infusion Solutions... "Increased Omega-3 Ratio"

Omaf Plus One·Omaf Plus One Ferry
Osong New Factory Operation... Portfolio Expansion
"Will Lead the Comprehensive Nutritional Infusion Market"

HK inno.N is expanding its market share by obtaining product approval for a total parenteral nutrition solution with an increased ratio of omega-3.

Overview of HK Inno.N Osong Plant. [Photo by HK Inno.N]

HK inno.N announced on the 11th that it received approval from the Ministry of Food and Drug Safety on the 7th for the total parenteral nutrition solutions 'Omap Plus Oneju' and 'Omap Plus Oneperi'. Omap Plus Oneju is intended for central venous administration, while Omap Plus Oneperi is for peripheral or central venous administration.

This product is a total parenteral nutrition solution (TPN) that supplies amino acids, electrolytes, glucose, and lipids all at once, used for patients who have difficulty eating and require nutritional supply via intravenous injection.

HK inno.N emphasized that both Omap Plus Oneju and Omap Plus Oneperi contain the highest amount of refined fish oil compared to currently available total parenteral nutrition solutions. Refined fish oil is known to contain large amounts of omega-3 fatty acids EPA and DHA, which help improve patients' immune function and regulate inflammatory responses. Additionally, the content of soybean oil, which contains a large amount of omega-6 involved in producing inflammatory factors, was reduced to balance the ratio of omega-6 to omega-3 at 1:1, enabling balanced lipid supply.

According to the phase 3 clinical trial results of the Omap Plus One series, the inflammatory cytokine (IL-6) that increased after surgery significantly decreased statistically, and blood levels of omega-3 fatty acids EPA and DHA significantly increased compared to the control drug. Nutritional management indicators and blood lipid concentrations were similar to those of the control drug, and no serious adverse reactions were reported.

Total parenteral nutrition solutions, also called TPN solutions, are used to supply nutrition to patients who cannot eat orally or via the gastrointestinal tract (tube), such as post-surgery patients. The product contains essential nutrients?glucose, amino acids, and lipids?divided into three separate chambers within a single infusion bag.

HK inno.N began research on the Omap Plus One series in 2017 and has now obtained approval. After registering the insurance price within this year, the product is scheduled to launch next year, aiming to further increase its market share in the high value-added total parenteral nutrition solution market.

Kwok Dalwon, CEO of HK inno.N, said, "The Omap Plus One series, a total parenteral nutrition solution developed in-house, is the result of the company's full research and development capabilities and will serve as another growth engine in the total parenteral nutrition solution market." He added, "We will not only expand overall infusion solution production with the completion of the new Osong infusion solution factory but also become a leading company in total parenteral nutrition solutions through new product approvals and expansion of the total parenteral nutrition solution production line."

HK inno.N entered the infusion solution business in 1992 and produces and distributes basic infusion solutions, special infusion solutions, and nutritional infusion solutions. It manufactures infusion solutions at the Daeso plant in Eumseong-gun, Chungbuk, and the Osong plant in Cheongju, Chungbuk. Combined, these two plants have an annual maximum production capacity of over 100 million infusion units.

Meanwhile, the domestic total parenteral nutrition solution market was estimated at 155 billion KRW as of last year. The average annual growth rate over the past four years is 5.2%, influenced by the aging society and increasing medical demand.

Logos of HK Inno.N's comprehensive nutritional infusion solutions Omaf Plus Wonju (left) and Omaf Plus Won Ferryju. [Image provided by HK Inno.N]

This content was produced with the assistance of AI translation services.